cff-version: 1.2.0
abstract: "<p>Effects of sex, age, EGFR mutation status and smoking status on immunotherapy.  we showed that the benefits for PFS and OS were similar in male and female, and in younger (< 65 years of age) and older (≥65 years of age) patients. EGFR mutation status and smoking status are two independent influencing factors. Regardless of EGFR mutation status, the ORR and PFS of current-smokers were better than those of never-smokers; The benefits of immunotherapy for other mutant subtypes except 19del, L858R and T790M were similar to those of EGFR wild-type; Former-smokers are a unique population who benefit poor from immunotherapy than never-smokers or current-smokers. </p>"
authors:
  - family-names: Tang
    given-names: Haibo
    orcid: "https://orcid.org/0000-0002-0871-2542"
  - family-names: Li
    given-names: Xiaoning
  - family-names: Cai
    given-names: Jianhong
  - family-names: wu
    given-names: xiaomin
title: "Data for the paper: ‘Effects of different factors on the efficacy of anti PD-(L)1 monotherapy in patients with advanced non-small cell lung cancer: An observational, retrospective cohort study’"
keywords:
version: 1
identifiers:
  - type: doi
    value: 10.4121/19606378.v1
license: CC BY-NC-SA 4.0
date-released: 2022-04-20